We have followed Xenon Pharmaceuticals (Nasdaq: XENE) for a very long time. We watched management methodically build azetukalner (AZK) from a development-stage focal onset seizure (FOS) product into an imminently commercial product and a potential pipeline-in-a-product franchise. Two weeks ago, the company took an important and expected step toward AZK’s commercial launch by submitting an NDA for FOS to the FDA. What investors didn’t expect was a cloud cast over AZK’s pipeline-in-a-product potential, as Xenon paused enrollment in all its neuropsychiatric studies due to unexpected side effects in its depression studies.
The stock sold off sharply, shedding roughly a third of its value. The selling was rational, to a point. The risk profile for AZK has changed, at least in neuropsych. Although we don’t believe these side effects will prove commercially fatal for AZK if it ultimately succeeds in one or more neuropsych indications, the timeline for franchise expansion has clearly been disrupted, justifying an initial downward re-rating.
However, we believe the selloff went too far. Xenon is now trading at a valuation below where it sat before unblinding its robust Phase 3 X-TOLE2 data, implying the market is discounting the core epilepsy business as well. This is a mistake, and for those who understand the foundational asset, the current valuation offers a compelling risk/reward setup. But make no mistake: more patience will be required, as the company has entered a catalyst vacuum with little chance of real clarity until the unblinded Phase 3 X-NOVA2 major depressive disorder (MDD) data arrives in the first quarter of 2027.
Nothing Has Changed, Or Maybe Just a Little
While investors spent the last week obsessing over the neuropsych pause, they shouldn’t lose sight of the anchor underpinning the entire company: Xenon’s core epilepsy franchise is de-risked and unaffected, and its nearest Kv7 competitor recently hit a safety speed bump.
First, the FOS NDA is officially at FDA. That submission is supported by two clean trials, including an unprecedented 42.7% median seizure reduction in X-TOLE2, and backed by more than 1,500 patient-years of exposure data with long-term extension tracking stretching past five years. Active enrollment in its other ongoing Phase 3 epilepsy programs, including the confirmatory FOS study (X-TOLE3) and the primary generalized seizure study (X-ACKT), continues without interruption.
Does the focal epilepsy label pick up a warning for neuropsych events? Very likely. But does that alter the commercial outlook in epilepsy? History suggests it barely matters.
Treating epilepsy has always been an exercise in managing neuropsych trade-offs. The most widely scripted anti-seizure medications in the world come bundled with psychiatric warnings, and epileptologists manage those risks as a matter of routine. A warning on AZK’s label won’t deter prescribers who are weighing manageable side effects against unprecedented seizure reduction.
Furthermore, what happened to Xenon’s primary Kv7 competitor is lost in the noise of Xenon’s headline. On September 10, Biohaven (Nasdaq: BHVN) filed a Form 8-K disclosing that the FDA placed a partial clinical hold on its competing Kv7 opener, opakalim (BHV-7000), pausing new patient screening in its ongoing Phase 3 RISE-2 trial due to questions about rodent metabolite characterization.
To be fair, this is far from fatal for Biohaven or its partner, SK Biopharmaceuticals. Dosing continues for more than 600 already-randomized patients across the program. Topline data from its fully enrolled pivotal RISE-3 study remain on track for the second half of this year, and management expects the clarifying nonclinical data to be available shortly. Nevertheless, pausing enrollment in an actively recruiting trial pushes out an already undefined timeline for a potential filing, extending Xenon’s first-mover advantage – never mind the daunting efficacy bar AZK has established. AZK’s NDA is already submitted, positioning the company for a commercial launch in late 2027 or early 2028, with no approved Kv7 competitors on the immediate horizon.
What Happened in Neuropsych
Others have already spilled plenty of ink dissecting the side effects that led to the company-induced pause, but the short version is straightforward: as patient exposure scaled up in Phase 3 under an untitrated 20 mg regimen, a subset of patients experienced mild-to-moderate confusion, difficulty speaking (aphasia), balance issues (ataxia), and in rare cases, transient psychosis. These side effects are not entirely novel; isolated psychiatric events have been observed at very low frequencies in the broader epilepsy program, where they were transient, manageable, and accepted as part of the trade-off for profound seizure control.
The market’s reaction, however, conflated two fundamentally different problems. Management’s working thesis is that these acute CNS events are exposure-driven onboarding issues that can be solved with gradual dose titration. Yet by halting the trials, the pause managed to cast a shadow over efficacy optimism in MDD and bipolar depression as well.
The valuation data show exactly how the Street reacted. Immediately before unblinding the pivotal Phase 3 X-TOLE2 results in March, Xenon had a market capitalization of roughly $3.8 billion. Backing out pro forma cash, the company traded at an enterprise value of approximately $3.1 billion. Today, with the market cap around $3.7 to $3.8 billion and a plump cash balance of roughly $1.25 billion, Xenon’s enterprise value has compressed to approximately $2.5 billion.
Think about that math: despite delivering an unprecedented 42.7% median seizure reduction in Phase 3, officially submitting its NDA, and watching its primary competitor run into an FDA partial clinical hold, Xenon’s enterprise value is more than $600 million lower today than it was before its Phase 3 FOS program was de-risked. That contraction confirms the market didn’t simply price in a timeline delay or an operational pause; it priced in a new safety overhang, wiped out near-term efficacy conviction in neuropsych, and took an extra bite out of the core epilepsy franchise in the process.
While management framed the clinical pause as voluntary, the probability of restarting any of these studies before X-NOVA2 reads out is essentially zero. As CEO Ian Mortimer noted during his TD Cowen fireside chat last week, the logistics of drafting dose-escalation protocols, clearing regulatory hurdles, and securing institutional review board approvals across trial sites mean that any potential restart date would essentially coincide with the Q1 2027 readout anyway. Regardless of the logistics, it makes little sense to restart the neuropsych studies until X-NOVA2 reads out and we know the drug actually works.
If there is a silver lining in all of this, it is that investors are getting the efficacy answer sooner. Continuing to enroll untitrated patients in X-NOVA2 was no longer viable once the safety signal emerged. But because recruitment had already reached ~360 patients, preserving roughly 90% statistical power to detect a 2.5-point placebo-adjusted difference on the primary HAM-D17 endpoint, capping the study let management avoid a compromised mid-trial protocol amendment and pulled the pivotal MDD readout forward into the first quarter of 2027
The M&A Disconnect: Why a Deal Won’t Happen Here
Epilepsy has seen a steady cadence of strategic M&A over the past 24 months. Lundbeck paid $2.6 billion for Longboard to acquire a Phase 3 asset for developmental and epileptic encephalopathy; UCB put up $1.15 billion for Neurona to secure an early-stage regenerative cell therapy for mesial temporal lobe epilepsy; Jazz acquired Actio for up to $1.3 billion to add rare genetic epilepsy programs to its Epidiolex franchise; and SK Biopharmaceuticals committed $350 million upfront for exclusive worldwide rights to Biohaven’s competing Kv7 platform. Strategics clearly want new epilepsy mechanisms, and earlier this summer there was plenty of market chatter that Xenon was a premier takeout target in the space.
Yet, anyone buying Xenon today in hopes of an imminent buyout is likely to be disappointed. With the recent selloff eroding roughly a third of Xenon’s market capitalization, the market has essentially stripped out all value for the neuropsych pipeline and taken an additional discount off the core epilepsy business. With over $1.2 billion in cash on the balance sheet, Xenon is not negotiating from a position of distress. They have an operational runway that extends into 2029 and no need to accept a fire-sale valuation that assigns zero credit to neuropsych. We think Xenon is highly unlikely to contemplate a transaction at this stage, or at any point before value is once again ascribed to the neuropsych franchise, which is unlikely to occur until X-NOVA2 is unblinded in the first quarter of 2027.
The Q4 Penalty Box: The Tax-Loss Grinder
Xenon appears inexpensive at these levels, but valuation alone is not a catalyst. Between now and year-end, Xenon faces a catalyst void. Investors expect the NDA to be accepted and Xenon to receive a 2H2027 PDUFA date. The American Epilepsy Society meeting in December will showcase 60-month open-label extension data, but those data offer little to no upside. The company is scheduled to complete two Phase 1 studies before year-end, one in its Nav1.7 program, the other in its next-generation Kv7 program. Investors are particularly interested in the Nav1.7 pain program, but we question whether Phase 1 safety data will be enough to spark the stock.
Earlier this year, a syndicate of premier healthcare funds took down a heavily upsized financing at $57 per share. In a year where the broader biotech tape has posted solid gains, seeing an institutional favorite suddenly sitting 30% underwater, with no needle-moving headlines left on the calendar, makes it a prime candidate for year-end tax-loss selling. Until that hypothetical overhang clears, the equity could remain range-bound.
The Bottom Line
The selloff reflects a classic institutional reset that went too far. By stripping out the pipeline-in-a-product multiple while Xenon waits to prove its depression efficacy, the Street also took an extra pound of flesh out of the epilepsy business. At an enterprise value of roughly $2.5 billion, the market isn’t only writing the neuropsych opportunity down to zero; it is valuing an NDA-stage asset below where it traded before Phase 3 data.
In other words, you are buying a de-risked epilepsy blockbuster at a pre-Phase 3 valuation, with the rest of the pipeline thrown in for free. For those willing to look past potential fourth-quarter tax-loss selling and a temporary news lull, this disconnect creates an exceptionally attractive entry point ahead of the unblinded Phase 3 MDD readout in early 2027.